Journal ArticleDOI
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,Carlton G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Fred K. L. Spijkervet,Michael T. Brennan,Salivary Gland Hypofunction,Xerostomia Section +24 more
Reads0
Chats0
TLDR
There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment.Abstract:
This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.read more
Citations
More filters
Journal ArticleDOI
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,C. G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Frederik Spijkervet,Michael T. Brennan +22 more
TL;DR: Salivary gland hypofunction and xerostomia are induced by radiotherapy in the head and neck region depending on the cumulative radiation dose to the gland tissue, and treatment focus should be on optimized/new approaches to further reduce the doses to the parotids.
Journal ArticleDOI
Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers
Arjan Vissink,James B. Mitchell,Bruce J. Baum,Kirsten H. Limesand,Siri Beier Jensen,Philip C. Fox,Linda S. Elting,Johannes A. Langendijk,Robert P. Coppes,Mary E. Reyland +9 more
TL;DR: This review addresses the pathophysiology underlying irradiation damage to salivary gland tissue, the consequences of radiation injury, and issues contributing to the clinical management of salivARY gland hypofunction and xerostomia.
Journal ArticleDOI
Interventions for the management of dry mouth: topical therapies.
TL;DR: There is no strong evidence from this review that any topical therapy is effective for relieving the symptom of dry mouth, and both integrated mouthcare systems and oral reservoir devices show promising results but there is insufficient evidence at present to recommend their use.
Journal ArticleDOI
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Noam Yarom,Noam Yarom,Charles L. Shapiro,Douglas E. Peterson,Catherine Van Poznak,Kari Bohlke,Salvatore L. Ruggiero,Salvatore L. Ruggiero,Cesar A. Migliorati,Aliya Khan,Archie Morrison,Archie Morrison,Holly Anderson,Barbara A. Murphy,Devena E. Alston-Johnson,Rui Amaral Mendes,Beth M. Beadle,Siri Beier Jensen,Deborah P. Saunders +18 more
TL;DR: In this paper, the authors provide guidance regarding best practices in the prevention and management of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer.
Journal ArticleDOI
Treatment of late sequelae after radiotherapy for head and neck cancer
Primož Strojan,Katherine A. Hutcheson,Avraham Eisbruch,Jonathan J. Beitler,Johannes A. Langendijk,Anne W.M. Lee,June Corry,William M. Mendenhall,Robert Smee,Alessandra Rinaldo,Alfio Ferlito +10 more
TL;DR: The available evidence on the use of different therapeutic strategies to alleviate common late sequelae of RT in head and neck cancer patients is reviewed, with a focus on the critical assessment of the treatment options for xerostomia, dysphagia, mandibular osteoradionecrosis, trismus, and hearing loss.
References
More filters
Journal Article
Does Lemon Candy Decrease Salivary Gland Damage After Radioiodine Therapy for Thyroid Cancer
Kunihiro Nakada,Tetsuya Ishibashi,Toshiki Takei,Kenji Hirata,Katsura Shinohara,Seiichi Katoh,S. Zhao,Nagara Tamaki,Yasushi Noguchi,Shiro Noguchi +9 more
TL;DR: An early start of sucking lemon candy may induce a significant increase in salivary gland damage, and lemon candy should not be given until 24 h after radioiodine therapy.
Journal ArticleDOI
Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
Todd H. Wasserman,David M. Brizel,Michael Henke,Alain Monnier,François Eschwege,Rolf Sauer,Vratislav Strnad +6 more
TL;DR: Amifostine administration during head-and-neck RT reduces the severity and duration of xerostomia 2 years after treatment and does not seem to compromise locoregional control rates, progression-free survival, or overall survival.
Journal ArticleDOI
Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
Marc W. Münter,Christian P. Karger,Simone Hoffner,Holger Hof,Christoph Thilmann,Volker Rudat,Simeon Nill,Michael Wannenmacher,Jürgen Debus +8 more
TL;DR: Using IMRT, it is possible to protect the parotid glands and reduce the incidence and severity of xerostomia in patients and the hypothesis that application of IMRT does not lead to increased local failure rates is supported.
Journal ArticleDOI
Acupuncture treatment of patients with radiation-induced xerostomia.
TL;DR: The results indicate that acupuncture might be a useful method for the treatment of radiation-induced xerostomia, and that superficial acupuncture should preferably not be used as placebo acupuncture.
Journal ArticleDOI
Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.
TL;DR: Patient self-reported, rather than physician-assessed scores, should be the main end points in evaluating xerostomia in patients receiving intensity-modulated radiotherapy for head-and-neck cancer.
Related Papers (5)
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,C. G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Frederik Spijkervet,Michael T. Brennan +22 more
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M. Nutting,Christopher M. Nutting,James P Morden,Kevin J. Harrington,Kevin J. Harrington,Teresa Guerrero Urbano,Shreerang Bhide,Catharine H. Clark,Elizabeth Miles,Aisha Miah,Kate Newbold,Mary Anne Lagmay Tanay,Fawzi Adab,Sarah Jefferies,Christopher D Scrase,Beng K. Yap,Roger A'Hern,M. Sydenham,M. Emson,Emma Hall +19 more